


February 25-27, 2020
Boston, MA, USA


Book By November 22
& Save Up To
\$900



8th Annual

Neurodegenerative Drug Development Summit

Overcoming Translational Research Challenges to Improve Clinical Efficacy



Your 32 Expert Speakers Include:



Michael Gold
Vice President, Neuroscience
Development
AbbVie



Christian Schubert
Global Head, External
Innovation
Servier



Richard Ransohoff
Venture Partner
Third Rock Ventures



Richard Hargreaves
Vice President, Head
Neuroscience & Imaging
Research & Early Development
Celgene



John Renger
Chief Scientific Officer
Cerevel Therapeutics



Pascal Sanchez
Director, Translational
Sciences
Denali Therapeutics



Lamya Shihabuddin
Head of Genetic Neurologic
Diseases
Sanofi



Ivana Rubino
Global Head of Medical
Alzheimer's
Biogen



Johan Luthman
Executive Vice President
& Head of Research &
Development
Lundbeck

Expertise Partner:



Program Partner:



Welcome to the 8th Annual Neurodegenerative Drug Development Summit

Gathering CNS Leaders for an Unrivalled Discussion Experience, Exploring the Latest Technology Advances to Improve Translation into the Clinic & Refreshing the Neurodegenerative Drug Development Approach

Harnessing positive progress and optimism in the neurodegenerative field, the **Neurodegenerative Drug Development Summit's** mission is to reinvigorate drug development and accelerate the success of therapeutics targeting neurodegenerative disorders.

With a disease agnostic agenda and developed alongside experts from **AbbVie, Merck, Servier, Takeda** and other leading CNS drug developers, the **Neurodegenerative Drug Development Summit** will deliver an industry-focused program with two content-focused streams tailored specifically to:

- Tackling the **translational challenges** hindering the successful development of the next generation of therapeutics including **navigating preclinical model limitations and seeking translatable biomarkers**
- **Exploring innovative opportunities** for neurodegenerative drug developers such as **gene therapy** and **emerging targets**
- **Encouraging provocative discussion and debate** around the fields most pressing challenges such as **investment strategies and precompetitive research**

Join **over 150 neurodegeneration experts** for unrivalled networking opportunities across 3 days, 5 interactive workshops and over 7 hours of dedicated networking time with your peers and new connections to secure future partnerships.

What other attendees say about the CNS Series:

“ Outstanding conference ”

Richard Wyse, Director of R&D, **The Cure Parkinson's Trust**

“ Impressive line-up of industry speakers ”

Sean Smith, Executive Director of Neuroscience, **Merck**

“ This summit provided an excellent opportunity to learn and exchange valuable insights and experience from some of the leaders in the field ”

Larry Brown, Chief Scientific Officer, **Noveome Biotherapeutics, Inc.**


Attend the Neurodegenerative Drug Development Summit to:




Discover emerging targets of neurodegeneration with **Biogen** for more **promising target identification and validation**




Explore the latest biomarker technologies to **improve disease detection and monitor disease progression** with the **Michael J Fox Foundation**



Discuss the gene therapy opportunity with **Sanofi** for a **promising therapeutic modality**



Analyze the value provided by preclinical models with **Lundbeck** to **improve clinical predictability and confident translation**



Discuss future business models for neurodegenerative drug development with **Pfizer** to **secure funding and attract investment accelerating successful therapeutic development**

“ Great meeting that has the right balance of science, drug discovery and development, and networking ” Jonathan Levenson, Senior Director, **Proclara BioSciences**

Your 32 Expert Speakers



Alison Mungenast
Principal Scientist &
Neuroscience Lead
Eisai



Amy Easton
Senior Scientific
Manager, Drug
Discovery
Genentech



Aparna Vasanthakumar
Principal Research
Scientist, Genomics
Research Centre,
AbbVie; Chair of PPSP
ADNI



Bob Switzer
Founder,
President & Chief
Scientific Officer
**NeuroScience
Associates**



Christian Schubert
Global Head,
External Innovation
Servier



David Donabedian
Chief Executive
Officer
Axial Therapeutics



Eric Schaeffer
Senior Director,
Neuroscience
Innovation
Janssen



Henrik Zetterberg
Professor
**University of
Gothenburg**



Ilaria Tassi
Lead Scientist
Alector



Ivana Rubino
Global Head of
Medical Alzheimer's
Biogen



James Gorman
Brain Targeting
Program, Wyss
Institute for
Biologically Inspired
Engineering
Harvard



Johan Luthman
Executive Vice
President &
Head, Research &
Development
Lundbeck



John Renger
Chief Scientific
Officer
**Cerevel
Therapeutics**



Jonathan Brotchie
Co-Founder,
Director &
President
Atuka Inc



Krystof Bankiewicz
President & Chief
Executive Officer
**Brain
Neurotherapy Bio,
Inc.**



Lamya Shihabuddin
Head of Genetic
Neurologic Diseases
Sanofi

Great presentations, I learned a great deal.
I'm glad that I took the time to attend. ▶▶

Richard IL Davis, President & Chief Executive
Officer, **Arbor Scientia**

Your 32 Expert Speakers



Laszlo Kiss
Executive Director,
WRD & Principal
Pfizer



Leslie Shinobu
Senior Director,
Clinical
Development
Biogen



Michael Gold
Vice President,
Neuroscience
Development
AbbVie



Nahome Fisseha
Assistant
Scientific Director,
Neuroscience
Clinical
Development
AbbVie



Olivier Danos
Chief Scientific Officer
REGENXBIO



Pascal Sanchez
Director,
Translational
Sciences
**Denali
Therapeutics**



Richard Hargreaves
Vice President, Head
Neuroscience &
Imaging Research &
Early Development
Celgene



Richard Ransohoff
Venture Partner
Third Rock Ventures



Ross Jeggo
Head of
Neuroscience
Research
Servier



Samantha Hutten
Senior Associate
Director, Research
Partnerships
Michael J Fox



Sheraz Khan
Director of the Khan
Lab
Harvard



Larry Brown
Executive Vice
President & Chief
Scientific Officer
**Noveome
Biotherapeutics,
Inc.**



Sid O'Bryant
Executive Director,
Institute for
Translational Research;
Professor, Department
of Pharmacology &
Neuroscience
**University of North
Texas Health Science
Center**



**Sophie Parmentier
Batteur**
Director,
Neuroscience
Discovery
**Merck Research
Laboratories**



Will Chen
Director Systems
Biology
Biogen



Yaming Wang
Senior Research
Scientist
Eli Lilly

High level, focused meeting, with overall very interesting presentations and discussion by decision makers in CNS research and development

Johan Luthman, Vice President, Clinical Development,
Eisai

Pre-Conference Workshops

Tuesday, February 25

Workshop A

8.30-11.30

Exploring Blood-Based Biomarkers of Neurodegeneration

Despite the lack of clinical progress for neurodegenerative disorders, the technology and research to characterise the diseases as well as develop diagnostic tools for earlier disease diagnosis and prognosis is rapidly advancing.


At this workshop, you will:

- Hear the latest research on fluid biomarkers of neurodegeneration
- Discover the technology advances that enable the analysis of blood samples
- Discuss the progress and potential opportunity that this technology will serve for neurodegenerative patients

Workshop Leaders:



Henrik Zetterberg
Professor
University of Gothenburg



Sid O'Bryant
Executive Director, Institute for Translational Research; Professor, Department of Pharmacology & Neuroscience
University of North Texas Health Science Center

Workshop B

8.30-11.30

Evaluating Gene Therapy for Neurodegenerative Disorders

The neurological drug development landscape is being transformed by gene therapies, with recent approvals for neuromuscular disorders. The application of gene therapy for neurodegenerative disorders is promising, despite its challenges such as delivery to target cells. Innovative vector technology is being developed to help improve the target engagement and cell specificity of gene therapy delivery.

Attend this workshop to:

- Assess the pros and cons of gene therapy as a therapeutic for neurodegenerative disease
- Explore the use of vector engineering to improve gene therapy delivery
- Discuss the promising research in this area

Workshop Leader:



Krystof Bankiewicz
President and CEO
Brain Neurotherapy Bio, Inc.

■ A great opportunity to meet like-minded individuals and discuss the common issues that we all face in drug discovery. Really competent speakers and a great overall atmosphere ■

Patrick Downey, Director, **UCB**

Pre-Conference Workshops

Tuesday, February 25

Workshop C

12.00-3.00

Exploring the Role of Neuroimmunology in Neurodegeneration & its Therapeutic Potential

Review the basic neuroimmunology of the brain to understand the different peripheral and central immune cells, their interactions and how they contribute to brain function or disease pathology. This session will focus on the interaction between innate immune pathways and their influence on neurodegeneration.

Join this workshop to:

- Improve your understanding of the different cells involved in the innate immune responses in the brain and understand how they are affected in neurodegeneration
- Explore different approaches for determining microglial function/dysfunction
- Review case studies where neuroimmunological mechanisms are used to target neurodegeneration

Workshop Leaders:



Yaming Wang
Senior Research Scientist
Eli Lilly



Ilaria Tassi
Lead Scientist
Alector

Workshop D

12.00-3.00

The Potential of AI & Digital Biomarker Applications to Support Drug Development

The development of digital biomarkers is crucial for accurately and objectively assessing neurodegenerative disorders. From digital health tools to mobile applications for drug development, this workshop will expose you to the best in class, interactive and innovative digital assessment technologies that capture meaningful and patient relevant data.

This workshop will:

- Explore digital technologies being developed to monitor neurodegenerative diseases
- Highlight the promising applications of this research
- Address the challenges of integrating digital technologies into clinical trials

Workshop Leader:



Sheraz Khan
Director of the Khan Lab
**Harvard
MGH & MIT**

Very good conference Christopher Missling, President, **Anavex Life Sciences Corp**

Pre-Conference Workshops

Tuesday, February 25

Workshop E

3:30-6:30

Navigating the Preclinical Space in Parkinson's Disease Drug Development: Genetic & Non-Genetic Based Programs

There are plenty of challenges for neurodegenerative drug developers as they progress to the clinic. This workshop will provide an in-depth discussion as to how to navigate these challenges to improve the quality of your preclinical research.

Attending this workshop will enable you to:

- Discuss the appropriate use of animal models, both rodent and non-human primate
- Explore biodistribution, PK and safety of test item
- Ensure target engagement and access to biofluids
- Identify key primary endpoints
- Design preclinical studies with a focus on de-risking clinical trials

Workshop Leader:



Jonathan Brotchie
Co-Founder, Director & President
Atuka Inc

■ ■ Excellent conference with a very good and diverse set of speakers and topics ■ ■

James Cassella, Chief Development Officer, **Concert Pharmaceuticals**

■ ■ It was a terrific conference with plenty of meaningful inputs ■ ■

Tatsuro Nakagawa, Manager, **Akros Pharma Inc.**

Conference Day One

Wednesday, February 26

Ross Jeggo

Head of Neuroscience
Research
Servier

8.00 Chair's Opening Remarks

The Neurodegenerative Drug Development State of Mind: Challenging Traditional Thinking for Promising Future Development

Christian Schubert

Global Head, External
Innovation
Servier

8.15 Neuroscience at the Inflection Point: Great News for Patients

- As the basic neuroscience is breaking rapidly, genetic discoveries of complex neurologic disease architecture are driving new hypotheses
- Deep phenotyping and digital medicine are revolutionizing our understanding of human experimental biology
- Exploring how new modalities are opening new avenues for CNS treatments
- Explaining how regulatory agencies are supporting new paths and redefinition of disease

Jonathan Brotchie

Co-Founder, Director
& President
Atuka Inc

8.45 The Evolving Landscape of Outsourcing Preclinical Research in Parkinson's Disease: A CRO's Perspective

- Analyzing the activities of a Parkinson's disease focussed CRO over the past decade to define where industry focus currently is and to identify where gaps or opportunities may be
- Discover what translational successes we have had across the spectrum of motor and non-motor symptoms?
- How are models of the degenerative process supporting the development of disease-modifying therapies, where do we go from here?
- Does the work being outsourced to CROs reflect the clinical need and scientific progress being made in the field, and if not, how can we evolve and refine the toolbox of models available for evaluating the most troublesome Parkinson's disease symptoms?

9.15 Panel Discussion: Previous Failures Upon Reflection: Drug Development vs Science

- Reviewing the neurodegenerative drug development landscape
- Is the lack of success a result of invalid targets?
- How can we apply the lessons learned to future research?



Ross Jeggo

Head of
Neuroscience
Research
Servier



Richard Ransohoff

Venture Partner
Third Rock
Ventures



John Renger

Chief Scientific
Officer
Cerevel
Therapeutics



Michael Gold

Vice President, Neuroscience
Development
AbbVie



9.45 Speed Networking

This session is the ideal opportunity to meet face-to-face with many of the brightest minds working in the CNS field and establish meaningful business relationships. Specifically designed to connect you with new contacts from the most active companies in the field, the renowned Speed Networking session will be one of the most valuable hours you will spend at the Neurodegenerative Drug Development Summit.

10.45 Morning Refreshments

Innovation Stream

Emerging Targets for Neurodegeneration: New Prospects

11.30 Choosing the Right Target: Using Human Genetics and Biology for Target Identification and Validation

- Increasing probability of success of programs through better target identification and validation
- Exploring experimental and analytical technologies to support neurodegenerative target validation
- Using genome scale data for drug discovery and development in neurodegenerative diseases

Will Chen, Senior Director, Translational Biology, **Biogen**

12.00 The Gut-Brain Axis in CNS diseases

- Discuss recent advances in the gut brain axis
- Highlight Parkinson's Disease and peripheral based etiology
- Encouraging clinical data in Autism via a gut-based approach

David Donabedian, Chief Executive Officer, **Axial Therapeutics**

12.30 A Neuroimmunology Perspective on Target Validation in Alzheimer's Disease

- Rationale behind G2D2's narrow focus on genetically-validated AD targets
- Selection of potential targets from human genetic data and assessment of functional directionality
- Challenges of target validation and compound screening in myeloid cell models
- Challenges of modelling the complex microglial environment in a drug discovery setting

Alison Mungenast, Principal Scientist & Neuroscience Lead, **Eisai**

Translational Stream

Optimizing the Value Provided by Preclinical Models for Improved Clinical Predictions

11.30 Interpreting the Data Provided by Animal Models for Optimal Drug Development – PK & PD Opportunities

- Discuss the value of preclinical research using *in vivo* models of neurodegeneration
- To what extent does a disease model help with clinical predictions?
- Highlight the benefit of PK & PD studies

Johan Luthman, Executive Vice President & Head of Research & Development, **Lundbeck**

12.00 The Promise of Human iPSC-based Models to Advance the Discovery of Therapies for Neurodegenerative Diseases

- The potential of iPSC could be revolutionary for studying neurodegenerative diseases, for which it is nearly impossible to obtain living cell samples from humans for studying the complexity of disease pathways
- Reviewing iPSC-derived neuronal cell models in early discovery of lead compounds, target validation and in phenotypic chemical or genetic screens to identify novel targets that have better chance of clinical translatability
- This presentation will provide examples of human iPSC-derived neurons to model neurodegenerative diseases and their applications to stimulate drug discovery in neuroscience

Sophie Parmentier-Batteur, Director, Neuroscience Discovery, **Merck Research Laboratories**

12.30 Seeking Improved Brain Shuttles Using Novel Endothelial 'Omics & Human *In Vitro* Assays

- Pursuing a novel proteomic and transcriptomic approach to identify new transport targets on brain endothelial cells
- Extending this approach to select and validate endothelial targets in patients with neurodegenerative diseases
- Optimizing a novel human transcytosis assay with improved characteristics compared to previously published assays
- Combining the transcytosis assay with humanized mice to select novel brain shuttle compounds to known targets
- Planning to select novel compounds to our emerging abundant enriched targets

James Gorman, Brain Targeting Program, Wyss Institute for Biologically Inspired Engineering, **Harvard**

1.00 Panel Discussion: Exploring Future Targets for Neurodegenerative Disease

- Discuss the current targets being explored for neurodegenerative diseases
- Are there unexplored avenues which should be studied?
- Where do we see the highest potential for therapeutic target success?

Will Chen, Senior Director, Translational Biology, **Biogen**

David Donabedian, Chief Executive Officer, **Axial Therapeutics**

Alison Mungenast, Principal Scientist & Neuroscience Lead, **Eisai**

1.30 Lunch & Networking

Exploring Gene Therapy as a Therapeutic for Neurodegeneration

2.30 Reviewing the Clinical Progress in Gene Therapies for Neurodegeneration

- Review the current clinical progress seen in various neurodegenerative diseases using gene therapy
- Explore MPS I, MPS II and CLN2 Disease as case studies for AAV therapy to treat neurodegenerative disorders
- Highlight future potential for other diseases and the planned pipeline expansion

Olivier Danos, Chief Scientific Officer, **REGENXBIO**

3.00 Assessing the Challenges of Gene Therapy: Delivery, Specificity & Safety

- Develop gene therapies for various neurodegenerative disorders and consider route of administration and optimized targeting, both regional and cell type
- Discuss capsid selection and capsid engineering for next generation gene therapies
- Consider the long-term effect and safety of gene therapy doses for neurodegenerative disorders

Lamya Shihabuddin, Head of Genetic Neurologic Diseases, **Sanofi**

3.30 Panel Discussion: Debating the Pros & Cons of Gene Therapy

- What are the greatest challenges for gene therapies targeting neurodegeneration?
- Which programs in the clinic look most promising?
- What other neurodegenerative diseases should be explored with gene therapy?

Lamya Shihabuddin, Head of Genetic Neurologic Diseases, **Sanofi**

Olivier Danos, Chief Scientific Officer, **REGENXBIO**

Krystof Bankiewicz, President and CEO, **Brain Neurotherapy Bio, Inc.**

4.00 Extended Q&A



1.00 Preclinical Model Audience Discussion

- Strategies to Predict Cognitive Function in Humans
- Discussing the opportunities provided by different *in vivo* and *in vitro* models
- This mastermind session will host interactive discussions amongst your tables and allow you to share your opinions with your peers on interpreting the value of different preclinical models of neurodegenerative diseases.

Amy Easton, Senior Scientific Manager, Drug Discovery, **Genentech**

Innovating Biomarker Discovery to Transform Neurodegenerative Drug Development

2.30 Introducing Digital Biomarkers to Stratify Patient Populations & Analyse Disease Progression

- Record digital neurodegenerative biomarker data
- Utilize machine learning and large data-set analysis to improve research efficiency
- Apply digital biomarkers and tools into clinical research

Sheraz Khan, Director of the Khan Lab, **Harvard, MGH & MIT**

3.00 Popular Microglial Target: Efficient, Robust Characterization of Microglial States

- Establishing the normal state of microglia across the entire brain
- Explore and quantify the variety of microglial states by type and by region
- Comparison of microglial states to other cellular activity

Bob Switzer, Founder, President & Chief Scientific Officer, **NeuroScience Associates**

3.30 Path to Target-Specific Biomarker Discovery

- Denali's approach to identify target and pathway biomarkers leveraging preclinical models and human samples
- Concrete examples with Denali data illustrating successes of our approach

Pascal Sanchez, Director, Translational Sciences, **Denali Therapeutics**

4.00 Audience Discussion: Biomarkers of Neurodegeneration

- Assess the current biomarkers used for neurodegenerative diseases
- Explore current biomarker discovery efforts
- How can we improve the translatability of neurodegenerative biomarkers?

This audience discussion will provide a platform for interactive discussions amongst your tables and allow you to share your opinions with your peers on biomarkers of neurodegeneration, both established and novel.

4.30 Afternoon Refreshments & Networking

Transforming Clinical Success in Neurodegenerative Drug Development

Michael Gold
Vice President,
Neuroscience
Development
AbbVie

5.30 Don't Enter the Clinic Without a Pilot Study

- Pilot studies, why do them?
- What sorts of designs make sense for neurodegenerative diseases?
- Is the data informative?

Eric Schaeffer
Janssen

Richard Hargreaves
Celgene

Ross Jeggo
Head of Neuroscience
Research
Servier

6.00 Transforming Neurodegenerative Drug Development with State-of-the-Art Technology

- Moving away from biology, pathology and neurodegenerative targets, how is the clinical landscape being transformed by advances in technology?
- What technological applications are proving to be accelerating neurodegenerative progress?
- Which emerging technologies should we keep an eye on?



6.30 Quick-Fire Poster Presentation Talks

Capturing the scientific highlights of the Neurodegenerative Drug Development Summit's Poster Session, this session will put the spotlight on three exceptional posters.

Ross Jeggo
Head of Neuroscience
Research
Servier

7.00 Chair's Closing Remarks



7.15 Scientific Poster Session

The learning at networking continues at the Poster Session, an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new, beneficial relationships. You will have the opportunity to present and review presentations displaying new data from neurodegenerative disease research, such as novel targets, progress with different therapeutic modalities and advances in translational tools.

“I liked the conference and the chance to interact with many of the sponsors”

David Walling, Chief Executive Officer, **CNS Network, LLC.**

Conference Day Two

Thursday, February 27

Ross Jeggo Head of Neuroscience Research Servier	8.30 Chair's Opening Remarks
Henrik Zetterberg Professor University of Gothenburg	8.45 Keynote Speaker: Reducing Undue Patient Burden with Development of Blood-Based Biomarkers – Goodbye Lumbar Puncture? • Technological breakthroughs allow for translating many of the cerebrospinal fluid biomarker assays into reliable blood tests • Blood remains a challenging matrix and key assay validation steps need to be taken to ascertain the reliability of the results • Discussing the success stories as well as failures in this space

9.15 Panel Discussion: Following in Oncology's Footsteps: Precompetitive Biomarker Work to Improve the Likelihood of Therapeutic Success

- Exploring how a precompetitive approach can transform the drug development landscape
- Discussing the initiatives supporting precompetitive biomarker studies
- Where is there resistance to sharing data – who needs to be persuaded?



Ross Jeggo
Head of Neuroscience Research, **Servier**



Samantha Hutten
Senior Associate Director, Research Partnerships
Michael J Fox



Aparna Vasanthakumar
Principal Research Scientist, Genomics Research Centre, **AbbVie**; Chair of PPSP, **ADNI**

9.45 Morning Refreshments & Networking

Innovation Stream

Addressing the Approval, Investment & Reimbursement Challenges of Neurodegenerative Drug Development

10.45 How Can Real World Evidence (RWE) Support Neurodegenerative Drug Development Throughout a Product's Lifecycle?

- Evolving role of RWE in regulatory and payer decisions
- Capturing the voice of patients in neurodegenerative drug development
- Role of RWE in enabling clinical practice changes

Ivana Rubino, Global Head of Medical Alzheimer's, **Biogen**

11.15 Exploring Intranasal Administration to Bypass the Blood-Brain Barrier

- ST266 is a neuroprotective, anti-inflammatory complex biologic derived from Amnion-derived Multipotent Progenitor Cells
- Targeted intranasal ST266 delivery reproducibly bypasses the blood-brain barrier
- Cautious preclinical safety and efficacy studies enable the regulatory pathway into clinical studies

Larry Brown, Executive Vice President & Chief Scientific Officer, **Noveome Biotherapeutics, Inc.**

Translational Stream

Exploring Successful Biomarker Integration into Clinical Trials

10.45 Reviewing Biochemical Biomarkers in PD & Associated Challenges

- Landscape assessment of biochemical biomarkers for PD (prognostic, predictive, progression, stratification)
- Addressing the challenges and associated solutions

Samantha Hutten, Senior Associate Director, Research Partnerships, **Michael J Fox Foundation**

11.15 Using the Alzheimer's Disease Neuroimaging (ADNI) Consortium to Provide Consistency in Data Collection & Analysis

- Role of ADNI in standardizing protocols and analysis pipelines for imaging, biofluid and genetic biomarkers
- ADNI's cooperative, precompetitive set-up and industry-facing role in validating biomarkers
- Use of ADNI-generated samples in the Alzheimer's association global biomarker standardization consortium

Aparna Vasanthakumar, Principal Research Scientist, Pharmacogenetics & Pharmacogenomics, Genomics Research Center, **AbbVie**

11.45 Lunch & Networking

**Unifying Our Approach to Treating Neurodegenerative Patients –
What Collaboration is Required?**

Leslie Shinobu
Senior Director,
Clinical Development
Biogen

12.45 Patient-Centric Drug Development to Optimize Drug Development Efficiency

- Key challenges in conducting neurodegenerative research, such as understanding patient need and defining new clinically relevant outcomes
- Need for Patient-Centric Drug Development to better fulfill our joint goals and overcome barriers to participation
- Examples of efforts being made to transform future clinical trials: the role of digital platforms and collaboration in the pre-competitive space

1.15 Panel Discussion: Combining Expertise & Resources – Which Stakeholders are Essential for Successful Drug Development



Ross Jeggo
Head of Neuroscience
Research
Servier



Laszlo Kiss
Executive Director, WRD
& Principal
Pfizer



Leslie Shinobu
Senior Director, Clinical
Development
Biogen

1.45 Afternoon Networking & Refreshments

Refreshing the Neurodegeneration Drug Development Approach

Nahome Fisseha
Assistant
Scientific Director,
Neuroscience Clinical
Development
AbbVie

2.45 Demonstration of Early Target Engagement & Practical Implications for Drug Developers & Patients

- Lessons learned in de-risking clinical development with respect to early target engagement
- Exploring case studies mostly from neuroscience and some beyond
- Providing context on impact of success/failure in this effort for stakeholders' (drug developers & patients) ability to advance the underlying research, including ability to have multiple "shots on goal"

3.15 Panel Discussion: Harnessing Optimism Towards Tackling Neurodegenerative Disease

What have we learned from the Neurodegenerative Drug Development meeting?
Setting future goals for neurodegenerative drug development?
Highlighting the opportunity for drug developers and the hope for patients



Pascal Sanchez
Director, Translational
Sciences
Denali Therapeutics



Nahome Fisseha
Assistant Scientific Director,
Neuroscience Clinical
Development
AbbVie



Ross Jeggo
Head of Neuroscience
Research
Servier

Ross Jeggo
Head of Neuroscience
Research
Servier

3.45 Chair's Closing Remarks

■ This cosy format of the meeting allowed to meet all the attendees and to have strong interactions ■
Naert Gaelle, Chief Operations Officer, CILcare

Partnership Opportunities

The **Neurodegenerative Drug Development Summit** will host **over 150 leading neurodegeneration experts** seeking solutions to help them to confidently translate into the clinic and develop successful neurodegenerative therapeutics.



Showcase your **preclinical services, advanced neurodegenerative preclinical models, biomarker innovations** and **AI and digital capabilities** to this unique industry audience to outcompete your

competitors and fulfill your 2020 business goals.


There are a variety of partnership opportunities at the **Neurodegenerative Drug Development Summit**, including speaking positions, brand exposure and sponsored networking sessions.

Please get in touch with us so we can start to build a bespoke partnership package with you to maximize your **2020 business potential**.

Audience Seniority



Attending Companies



Expertise Partner:

Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson's disease and

related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and *in-vivo* imaging services to aid development of novel therapeutics.

www.atuka.com



Program Partner:

Proprietary MultiBrain® technology powers NSA's simultaneous sectioning, and expertly-guided staining, of up to 40 neuronal tissues in one

MultiBrain® block, achieving uniform processing across all 40 tissues. Implementing NSA's Large Format™ technology enables sectioning and staining of intact human brain hemispheres and yields comprehensive, uninterrupted vantage and analysis of the ultimate target. Coupling these mass production technologies with cutting-edge digital image capture and hosting, along with contemporary analysis tools increasingly powered by AI, rapidly produces rich data, and dramatically reduces R&D times.

www.NSALabs.com

Get Involved



Okeefe Ogholo

Business Development Manager

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

-  www.world-ndd.com/take-part/register/
-  Tel: +1 617 455 4188
-  Email: register@hansonwade.com

- 1 Discuss the promising future of neurodegenerative drug development with your peers to **guide your future research**
- 2 Discover novel targets, optimized approaches and technology advances to **accelerate the success of your neurodegenerative candidate**
- 3 Network with key industry thought-leaders in the neurodegenerative field to **share, learn and connect for future collaborations**

SECURE YOUR PLACE

Standard Price	Book by November 22	Standard Price
Gold: Conference + 3 Workshops	\$3,896 (save \$1,200)	\$4,496 (save \$600)
Silver: Conference + 2 Workshops	\$3,497 (save \$900)	\$4,097 (save \$300)
Bronze: Conference + 1 Workshop	\$2,998 (save \$700)	\$3,598 (save \$100)
Conference Only	\$2,399 (save \$600)	\$2,999
Workshop only	\$699	

Small Biotech Rate	Book by November 22	Standard Price
Gold: Conference + 3 Workshops	\$2,196 (save \$1,200)	\$2,896 (save \$600)
Silver: Conference + 2 Workshops	\$2,097 (save \$900)	\$2,697 (save \$300)
Bronze: Conference + 1 Workshop	\$1,798 (save \$700)	\$2,398 (save \$100)
Conference Only	\$1,399 (save \$600)	\$1,999
Workshop only	\$499	

Team Discounts*

- 2-3 delegates - **10% discount**
- 4 delegates - **20% discount**
- 5+ delegates - **30% discount**

Our morning workshops, and afternoon workshops, run parallel to each other. To make sure you take full advantage of the meeting, we encourage you to invite your colleagues so you access all the workshops at the pre-conference day and attend each stream on the main agenda.

***T&Cs Apply:** A start-up discount is available for newer, less established drug developers. Please contact us for more details on eligibility criteria. All bookings at this rate are subject to organizer approval. For academic rates, please contact us at register@hansonwade.com



Venue

Hyatt Regency Boston
1 Avenue de Lafayette, Boston, MA, 02111
For further information or assistance, please visit
www.hyatt.com/en-US/hotel/massachusetts/hyatt-regency-boston/bosto

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage, or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH